Related Experiment Videos
Psoriasis induced by topical imiquimod
Jason K Wu1, Greg Siller, Geoff Strutton
1Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
The Australasian Journal of Dermatology
|February 14, 2004
Summary
Topical imiquimod cream can trigger localized psoriasis flares at application sites in patients with pre-existing psoriasis. This reaction may progress to a generalized psoriatic eruption, even after treatment cessation.
Area of Science:
- Dermatology
- Oncology
Background:
- Psoriasis is a chronic autoimmune disease.
- Imiquimod is a topical immune response modifier used to treat skin cancers.
Observation:
- A patient with long-standing stable psoriasis was treated with topical imiquimod for basal cell carcinomas.
- Psoriasiform changes occurred at all three imiquimod application sites.
- The patient later developed a disseminated psoriatic eruption.
Findings:
- Topical imiquimod can induce localized psoriasis at application sites.
- Psoriasis provocation may occur even after imiquimod treatment completion.
- The induced psoriasis responded to conventional treatments.
Implications:
- Clinicians should be aware of the potential for imiquimod to trigger or exacerbate psoriasis.
- Careful monitoring is needed in psoriatic patients undergoing imiquimod therapy.
- This highlights the complex interplay between immune modulation and autoimmune skin conditions.